This in vitro study demonstrates that metformin suppresses cancer cell migration in KEAP1-deficient lung adenocarcinoma cells primarily through NAD+ depletion rather than AMPK activation. The researchers showed that supplementing with nicotinamide mononucleotide (NMN) restored cellular motility in metformin-treated cells, directly implicating NAD+ availability as the mechanistic driver. The finding has significant implications for practitioners considering NAD+-boosting supplements alongside conventional cancer therapies or metabolic interventions.
For your business
NMN restored motility in metformin-treated cancer cells in vitro; consider NAD+ supplementation timing when patients use metformin.